Literature DB >> 23458595

Malignant hypertension in patients treated with vascular endothelial growth factor inhibitors.

Jara Caro1, Enrique Morales, Eduardo Gutierrez, Luis Miguel Ruilope, Manuel Praga.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23458595      PMCID： PMC8033826          DOI： 10.1111/jch.12052

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN： 1524-6175            Impact factor:   3.738


× No keyword cloud information.
  10 in total

1.  Long-term renal survival in malignant hypertension.

Authors:  Roberto González; Enrique Morales; Julian Segura; Luis M Ruilope; Manuel Praga
Journal:  Nephrol Dial Transplant       Date:  2010-03-17       Impact factor: 5.992

2.  A preeclampsia-like syndrome characterized by reversible hypertension and proteinuria induced by the multitargeted kinase inhibitors sunitinib and sorafenib.

Authors:  Tejas V Patel; Jeffrey A Morgan; George D Demetri; Suzanne George; Robert G Maki; Michael Quigley; Benjamin D Humphreys
Journal:  J Natl Cancer Inst       Date:  2008-02-12       Impact factor: 13.506

Review 3.  Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis.

Authors:  Xiaolei Zhu; Shenhong Wu; William L Dahut; Chirag R Parikh
Journal:  Am J Kidney Dis       Date:  2007-02       Impact factor: 8.860

4.  Mechanisms of hypertension associated with BAY 43-9006.

Authors:  Maria Luisa Veronese; Ari Mosenkis; Keith T Flaherty; Maryann Gallagher; James P Stevenson; Raymond R Townsend; Peter J O'Dwyer
Journal:  J Clin Oncol       Date:  2006-01-30       Impact factor: 44.544

5.  Rapid development of hypertension and proteinuria with cediranib, an oral vascular endothelial growth factor receptor inhibitor.

Authors:  Emily S Robinson; Ursula A Matulonis; Percy Ivy; Suzanne T Berlin; Karin Tyburski; Richard T Penson; Benjamin D Humphreys
Journal:  Clin J Am Soc Nephrol       Date:  2010-01-07       Impact factor: 8.237

Review 6.  Renal toxicity of targeted therapies.

Authors:  Ronan J Kelly; Bertrand Billemont; Olivier Rixe
Journal:  Target Oncol       Date:  2009-05-06       Impact factor: 4.493

7.  VEGF inhibition and renal thrombotic microangiopathy.

Authors:  Vera Eremina; J Ashley Jefferson; Jolanta Kowalewska; Howard Hochster; Mark Haas; Joseph Weisstuch; Catherine Richardson; Jeffrey B Kopp; M Golam Kabir; Peter H Backx; Hans-Peter Gerber; Napoleone Ferrara; Laura Barisoni; Charles E Alpers; Susan E Quaggin
Journal:  N Engl J Med       Date:  2008-03-13       Impact factor: 91.245

Review 8.  Angiogenesis inhibitor therapies: focus on kidney toxicity and hypertension.

Authors:  Hassane Izzedine; Olivier Rixe; Bertrand Billemont; Alain Baumelou; Gilbert Deray
Journal:  Am J Kidney Dis       Date:  2007-08       Impact factor: 8.860

Review 9.  Management of hypertension in angiogenesis inhibitor-treated patients.

Authors:  H Izzedine; S Ederhy; F Goldwasser; J C Soria; G Milano; A Cohen; D Khayat; J P Spano
Journal:  Ann Oncol       Date:  2009-01-15       Impact factor: 32.976

Review 10.  Renal effects of anti-angiogenesis therapy: update for the internist.

Authors:  Faina Gurevich; Mark A Perazella
Journal:  Am J Med       Date:  2009-04       Impact factor: 4.965
  10 in total
  7 in total

1.  Clinical risk factors for the development of hypertension in patients treated with inhibitors of the VEGF signaling pathway.

Authors:  Ole-Petter R Hamnvik; Toni K Choueiri; Alexander Turchin; Rana R McKay; Lipika Goyal; Michael Davis; Marina D Kaymakcalan; Jonathan S Williams
Journal:  Cancer       Date:  2014-09-18       Impact factor: 6.860

2.  Vascular endothelial growth factor: a novel potential therapeutic target for hypertension.

Authors:  Hui Tao; Kai-Hu Shi; Jing-Jing Yang
Journal:  J Clin Hypertens (Greenwich)       Date:  2013-06-03       Impact factor: 3.738

3.  Reply to vascular endothelial growth factor: a novel potential therapeutic target for hypertension.

Authors:  Enrique Morales; Morales Enrique; Jara Caro; Caro Jara
Journal:  J Clin Hypertens (Greenwich)       Date:  2013-05-17       Impact factor: 3.738

Review 4.  Vascular Complications of Cancer Chemotherapy.

Authors:  Alan C Cameron; Rhian M Touyz; Ninian N Lang
Journal:  Can J Cardiol       Date:  2015-12-28       Impact factor: 5.223

5.  Incidence and risk of hypertension with lenvatinib in treatment of solid tumors: An updated systematic review and meta-analysis.

Authors:  Hongxiao Wu; Xiaoyan Ding; Yongchao Zhang; Wei Li; Jinglong Chen
Journal:  J Clin Hypertens (Greenwich)       Date:  2022-05-10       Impact factor: 2.885

6.  Treatment of sunitinib-induced hypertension in solid tumor by nitric oxide donors.

Authors:  L León-Mateos; J Mosquera; L Antón Aparicio
Journal:  Redox Biol       Date:  2015-09-10       Impact factor: 11.799

7.  Impaired Neovascularization and Reduced Capillary Supply in the Malignant vs. Non-malignant Course of Experimental Renovascular Hypertension.

Authors:  Andrea Hartner; Lisa Jagusch; Nada Cordasic; Kerstin Amann; Roland Veelken; Johannes Jacobi; Karl F Hilgers
Journal:  Front Physiol       Date:  2016-08-30       Impact factor: 4.566
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.